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Epstein-Barr virus (EBV) latency gene expression in lymphoblastoid cell lines is regulated by EBNA2.
However, the factors regulating viral expression in EBV-associated tumors that do not express EBNA2 are
poorly understood. In EBV-associated tumors, EBNA1 and frequently LMP1 are synthesized. We found that an
alternative latent membrane protein 1 (LMP1) promoter, L1-TR, located within the terminal repeats is active
in both nasopharyngeal carcinoma and Hodgkin’s disease tissues. Examination of the L1-TR and the standard
ED-L1 LMP1 promoters in electrophoretic mobility shift assays revealed that both promoters contain func-
tional STAT binding sites. Further, both LMP1 promoters responded in reporter assays to activation of
JAK-STAT signaling. Cotransfection of JAK1 or v-Src or treatment of cells with the cytokine interleukin-6
upregulated expression from ED-L1 and L1-TR reporter plasmids. Cotransfection of a dominant negative
STAT3b revealed that STAT3 is likely to be the biologically relevant STAT for EBNA1 Qp and LMP1 L1-TR
promoter regulation. In contrast, LMP1 expression from ED-L1 was not abrogated by STAT3b, indicating that
the two LMP1 promoters are regulated by different STAT family members. Taken together with the previous
demonstration of JAK-STAT activation of Qp driven EBNA1 expression, this places two of the EBV genes most
commonly expressed in tumors under the control of the same signal transduction pathway. Immunohisto-
chemical analyses of nasopharyngeal carcinoma tumors revealed that STAT3, STAT5, and STAT1 are consti-
tutively activated in these tumors while STAT3 is constitutively activated in the malignant cells of Hodgkin’s
disease. We hypothesize that chronic or aberrant STAT activation may be both a necessary and predisposing
event for EBV-driven tumorigenesis in immunocompetent individuals.
Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus
that, after primary exposure, maintains a latent infection for
the life of the individual. Approximately 1 to 50 per 106 circu-
lating B cells in healthy seropositive individuals carry the EBV
genome, and the site of long-term latency has been identified
as the G0 memory B cell (39). EBV infection elicits a strong
immune response (44), and in general viral persistence is con-
trolled by the host and is asymptomatic. However, one conse-
quence of lifelong infection is the potential for the develop-
ment of EBV-associated malignancies, which include Burkitt’s
lymphoma, nasopharyngeal carcinoma (NPC), Hodgkin’s dis-
ease, lymphoproliferative disease in immunocompromised pa-
tients, primary central nervous system lymphoma in AIDS pa-
tients, nasal T-cell lymphoma, a subset of gastric carcinoma,
and possibly also a subset of primary liver and breast cancers
(2, 3, 43, 51).
On initial EBV infection, and in latently infected lympho-
blastoid cell lines in culture, the full spectrum of EBV latency
genes is expressed. The Wp promoter, which is regulated by
B-cell-specific factors, is responsible for the initial transcrip-
tion of the nuclear EBNAs, EBNA1, EBNA2, EBNA3A,
EBNA3B, EBNA3C, and EBNA-LP (32). EBNA2, which
functions as a transcriptional activator, then enforces a switch
to Cp promoter-driven EBNA synthesis and also regulates
synthesis of the LMP1 and LMP2 latency membrane proteins.
However, EBNA2 is detected in EBV-associated malignancies
only in the context of immunosuppression, presumably because
the Cp-driven EBNA3 family proteins elicit a robust CD8
cell-mediated immune response (44). In EBV-associated tu-
mors in immunocompetent patients, the Cp is repressed by
methylation (1, 41). An alternative TATA-less promoter, Qp
(40, 46), is used to express EBNA1 in the absence of the
immunogenic EBNAs, and LMP1 is also frequently expressed.
EBNA1 binds to the origin of latent DNA replication, oriP,
and is required for maintainance of the episomal form of the
latent EBV genome (35, 42, 60). LMP1, an integral membrane
protein, is essential for EBV-driven B-cell immortalization and
induces transformation in primary Rat1 cells (56). The trans-
forming ability of LMP1 is explicable in large part by its func-
tioning as a constituitively activated tumor necrosis factor
(TNF) receptor that mimics signaling by the B-lymphocyte
activation antigen CD40 (19, 24, 55). The cytoplasmic carboxy
terminus of LMP1 interacts with TNF-receptor associated fac-
tors and with the TNF receptor-associated death domain pro-
tein to activate NF-kB and JNK (c-Jun N-terminal kinase)
signaling (17, 29).
It has been unclear how EBV gene expression in tumors is
regulated in the absence of EBNA2. We recently provided
evidence that the EBNA1-Qp promoter contains binding sites
for STATs and is activated in transient expression assays by
stimulation of JAK (Janus kinase)-STAT (signal transducer
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and activator of transcription) signaling (12). The JAK-STAT
pathway transduces signals from receptor-bound cytokines and
growth factors to the nucleus (4, 47). Ligand-induced receptor
aggregation leads to autophosphorylation of the receptor-as-
sociated JAKs followed by tyrosine phosphorylation of the
receptor. The receptor phosphotyrosines serve as docking sites
for the SH2 domain of STAT monomers, which are then them-
selves tyrosine phosphorylated either directly by JAKs or by
other nonreceptor protein tyrosine kinases such as c-Src (47).
The STAT family of proteins consists of seven members that
reside in the cytoplasm. Tyrosine phosphorylation leads to
SH2-mediated homo- or heterodimerization and translocation
to the nucleus, where the STATs bind to their target DNA rec-
ognition sequences and activate transcription. STAT transcrip-
tional activity is further modulated by phosphorylation of a
critical serine residue in the transactivation domain. Mitogen-
activated protein kinases (MAPK), JNK, and protein kinase C
have been implicated in serine phosphorylation of different
STAT family members (4). In normal cell signaling events,
STAT activation is transient. Negative regulation is produced
by dephosphorylation of signaling intermediates by protein
tyrosine phosphatases, by the SOCS family of JAK inhibitors,
and by the induction of STAT inhibitors such as PIAS (protein
inhibitor of activated STAT) (47, 50).
Several oncogenes function by constituitively activating STAT
signaling. A well-characterized example is v-Src, which induces
constituitive tyrosine phosphorylation of STAT3, STAT5, and
STAT1 (11, 61, 62). The association between aberrant STAT
activation and v-Src oncogenic activity was strengthened by the
demonstration that constituitive activation of STAT3 by mod-
ification of the SH2 domain results in a protein that is able to
induce cells to form colonies in soft agar and tumors in nude
mice (5, 15). Aberrant activation of JAK-STAT signaling has
also been described in human cancers. The chromosomal trans-
location that gives rise to the Tel-JAK2 fusion protein in acute
lymphocytic leukemia creates an aberrantly activated JAK2
kinase by forced dimerization of the kinase through the dimer-
ization domain of the Ets protein fusion partner (9). In addi-
tion, the tumor cells in malignancies such as breast cancer,
head and neck cancers, and a variety of leukemias and lym-
phomas contain increased levels of activated nuclear STATs,
frequently STAT3 or STAT5 (4, 23, 57, 58).
To assess the contribution of STAT signaling to EBV latency
gene expression, we examined LMP1 transcription and found
that both the standard LMP1 promoter and an alternative
LMP1 promoter located further upstream in the viral terminal
repeats are STAT responsive. Thus, two EBV genes commonly
expressed in tumors, EBNA1 and LMP1, are regulated by this
pathway. Further, an immunohistochemical analysis of samples
from patients with the EBV-associated malignancies NPC and
Hodgkin’s disease identified nuclear activated STATs within
tumor cells. We believe that STATs, and in particular STAT3,
are a driving force for EBV gene expression in tumors and
suggest that disregulation of the JAK-STAT pathway may be a
predisposing event for EBV-associated tumorigenesis.
MATERIALS AND METHODS
Cells and tissues. The JAK1 mutant (U4A), TYK2 mutant (U1A), and wild-
type parental (2fTGH) cell lines were a generous gift of G. Stark (34). These cells
were maintained in Dulbecco’s modified Eagle’s medium plus 10% fetal bovine
serum and hygromycin (250 mg/ml). The EBV-positive B-cell line B95-8 was
grown in RPMI 1640 plus 10% fetal bovine serum. Induction with interleukin-6
was achieved by incubating B95-8 cells in medium plus 100 ng of human inter-
leukin-6 (IL-6) (R&D Systems, Minneapolis, Minn.) per ml for 48 h before
harvesting the cells for RNA extraction. NPC tissues and paraffin sections were
obtained from Queen Mary Hospital, Hong Kong, and Sun Yat-Sen Medical
University Tumor Hospital, Guangzhou, China, respectively. Hodgkin’s disease
samples were obtained from the Department of Pathology, Johns Hopkins Hos-
pital.
Plasmids. The LMP1-chloramphenicol acetyltransferase (CAT) reporter
pLRS324 was obtained from L. Rymo (21). L1TRp-CAT and L1TR(mt)p-CAT
reporters were constructed in pCAT-BASIC (Promega). L1TRp-CAT contains
DNA sequences from coordinates 169981 to 170317 of the EBV genome. In
L1TR(mt)p-CAT, core sequences of the STAT binding site were mutated (TT
CCTGGAA to ggaCTcGtg). The Qp-CAT reporter expresses CAT from the
EBV latency Q promoter and has been previously described (12). Expression
plasmids for STAT3b and v-Src were gifts from R. Jove (6, 54), and the JAK1
expression vector has been described previously (12).
CAT assays. HeLa cells were transfected using the calcium phosphate proce-
dure (12), and U1A, U4A and 2fTGH cells were transfected using SuperFectant
(Qiagen) as specified by the manufacturer. Cells were transfected with 1 or 2 mg
of reporter DNA and 1 or 2 mg of effector DNA, and total transfected DNA was
equalized using vector DNA. Cells were harvested 30 to 40 h after transfection.
Reporter activity was quantitated as previously described (12) using an Instant-
Imager (Beckman Instruments).
Electrophoretic mobility shift assay. Purified, activated STAT1 and STAT4
proteins were generous gifts of T. Hoey, Tularik, Calif. (59). The sequence of the
sense strand of the double-stranded DNA probes and competitor oligonucleo-
tides are as follows, with introduced mutations shown in lowercase: 59-CATGT
TATGCATATTCTTGTAAGTGCATG (STAT1), 59-GAGCTTGATTTCCCC
GAAATGATGAGCGATC (STAT4), 59-GATCGGGGGCCGCGCATTCCTG
GAAAAAGTGGAGGG (L1TR), 59-GATCGGGGGCCGCGCAggaCTcGtG
AAAGTGGAGGG [L1TR(mt)], and 59-GATCCGGGTACAGATTTCCCGA
AAGCGGCGGTG (ED-L1). The Qp and control Flag oligonucleotides and the
electrophoretic mobility shift assay (EMSA) conditions were as previously de-
scribed (12). Anti-STAT4 and anti-Flag polyclonal antibodies used for supershift
assays were obtained from Santa Cruz, Santa Cruz, Calif., and Sigma, St. Louis,
Mo., respectively.
Northern and RT-PCR analyses. RNA was prepared from fresh NPC biopsy
specimens as previously described (14). Oligo(dT)-enriched RNA (5 mg) was
fractionated by agarose-formaldehyde gel electrophoresis, transferred to a Hy-
bond N membrane (Amersham), and probed with a 32P-labeled BamHI Nhet
EBV DNA fragment. RNA from B95-8 cells and Hodgkin’s disease tissue were
prepared using the QuickPrep Micro RNA purification kit (Pharmacia-Amer-
sham) and amplified by reverse transcription PCR (RT-PCR) using the L1TR
primers (position 168928) 59-GCAGATTACACTGCCGCTTC and (position
169831) 59-CCAGAGCATCTCCAATAAGTAG. PCR products were visualized
by Southern blotting using a 32P-end-labeled LMP1 oligonucleotide probe,
(position 169455) 59-CTCTCAAGGTCGTGTTCCATC. Oligonucleotides for
EBER1 amplification and detection were as described previously (13).
Immunohistochemistry. Paraffin sections of NPC and Hodgkin’s disease tissue
were analyzed for STAT expression using anti-STAT1, anti-STAT5, and anti-
STAT3 primary antibodies (Santa Cruz) at a 1:300 dilution. Positive interactions
were visualized using the StrpABComplex/horseradish peroxidase Duet kit
(Dako) as specified by the manufacturer. In control samples, the primary anti-
bodies were replaced with normal rabbit serum. Samples were counterstained
with hematoxylin.
RESULTS
Alternative LMP1 promoter usage in tumor samples. EBV
LMP1 is essential for in vitro immortalization of B lympho-
cytes and is expressed in EBV-associated malignancies such as
NPC and Hodgkin’s disease (32, 43). The ED-L1 promoter is
used to express LMP1 in B lymphoblastoid cell lines, but an
alternative promoter located within the viral terminal repeats,
L1-TR, has been described in NPC (45, 53). L1-TR is located
approximately 600 bp upstream of ED-L1 (Fig. 1a) and gives
rise to a larger (3.5-kb) transcript compared to the 2.8-kb ED-
L1-initiated mRNA. The two transcripts use the same ATG
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initiator, and hence the encoded LMP1 protein is identical.
Transcription from the L1-TR promoter in NPC tumor tissue
is illustrated in Fig. 1b, in which Northern blot analysis de-
tected the 3.5-kb LMP1 mRNA. Low levels of the ED-L1-
initiated 2.8-kb LMP1 transcript were also observed in one of
the NPC samples (Fig. 1b). LMP1 expression is particularly
prominent in EBV-positive Hodgkin’s disease (30), and we
therefore examined a sample of Hodgkin’s disease tissue for
L1-TR promoter usage. RT-PCR was performed using the P1
and P2 primers (Fig. 1a), which specifically detect L1-TR-
initiated transcripts. A 749-bp product that reacted with an
LMP1-specific oligonucleotide probe was detected by South-
ern blotting (Fig. 1c), indicating L1-TR usage in EBV-positive
Hodgkin’s disease. (The larger product was detected in the
absence of the RT reaction and is amplified from EBV geno-
mic DNA.)
The ED-L1 and L1-TR LMP1 promoters bind STATs. The
ED-L1 promoter is complexly regulated and responds to
EBNA2 in lymphoblastoid cell lines. However, EBNA2 is not
expressed in EBV-associated tumors in immunocompetent
hosts, suggesting a greater role for cellular factors in this set-
ting. The activity of the TATA-less L1-TR promoter is mod-
ulated by the Sp1 and Sp3 transcription factors (45, 53). We
recently demonstrated that the EBV Qp promoter that drives
EBNA1 expression is activated by the JAK-STAT signaling
pathway. We were intrigued by the possibility that this pathway
might play a central role in the regulation of EBV latency gene
expression in tumors, and examination of the ED-L1 and
L1-TR sequences revealed potential STAT binding sites in
each promoter (Table 1).
STATs dimerize, enter the nucleus, and bind to DNA when
they are activated by tyrosine phosphorylation. STAT family
proteins recognize similar DNA sequences, and it is not pos-
sible to predict which STATs might bind to the LMP1 promot-
ers. We had available purified, activated STAT1 and STAT4
and used these reagents to test whether the LMP1 promoters
contained functional STAT binding sites. EMSAs were per-
formed using 32P-labeled oligonucleotide probes containing
ED-L1 and L1-TR sequences (Fig. 2). STAT1 bound strongly
to both the ED-L1 and L1-TR probes but did not bind to the
latency Qp probe. STAT4 also bound to the ED-L1 and L1-TR
probes and, less strongly, to the Qp probe (Fig. 2a). To estab-
lish the specificity of the STAT binding, competition and su-
pershift assays were performed using the LMP L1-TR probe
and purified, activated STAT4 (Fig. 2b). The STAT4 com-
plexes were competed away by excess unlabeled STAT4 bind-
ing-site oligonucleotide but not by an irrelevant olignucleotide
containing the Flag epitope (Flag). Binding was also competed
effectively by unlabeled L1-TR oligonucleotide but not by an
L1-TR oligonucleotide carrying mutations within the STAT
binding sequence (L1-TRmt). Addition of anti-STAT antibody
generated a supershifted complex. No supershifted complex
was formed using a control antibody (anti-Flag). These results
demonstrate that the STAT sequences in the LMP1 promoters
are functional binding sites. It should be noted that different
STATs recognize very similar binding sites. The in vitro bind-
ing by STAT1 and STAT4, while demonstrating that these
STATs are capable of binding to the EBV latency promoters,
does not necessarily mean that they will be the STAT family
members that regulate the promoters in vivo.
Activation of the L1-TR LMP1 promoter by the JAK-STAT
pathway. Cytoplasmic STATs are tyrosine phosphorylated by
JAKs as part of a signaling pathway that is initiated by cytokine
or growth factor binding at the cell surface. The JAK protein
tyrosine kinase family consists of JAK1, JAK2, JAK3, and
TYK2. To test the L1-TR promoter for responsiveness to JAK-
STAT signaling, transient-expression assays were performed
using an L1-TR promoter-CAT reporter. Cotransfection of
L1-TRp–CAT with a JAK1 expression vector substantially in-
creased reporter activity over that observed in cells transfected
with L1-TRp–CAT alone. IL-6 is a cytokine that influences B
and T-cell growth and differentiation and is an important me-
diator of acute-phase immune responses (27). The IL-6 recep-
tor signals through JAK1, JAK2, and TYK2, and the signaling
activates STAT3 and STAT1 (47). Treatment of transfected
cells with IL-6 also increased L1-TRp–CAT reporter activity
(Fig. 3a).
Consistent with the observed increase in L1-TRp–CAT ex-
pression upon activation of JAK-STAT signaling, loss of JAK
activity led to a corresponding decrease in reporter activity
FIG. 1. LMP1 promoter usage in EBV-associated tumors. (a) Di-
agram of the LMP1 gene, showing the exon structure and the relative
positions of the standard promoter (pED-L1) and the terminal repeat
(TR) promoter previously identified in NPC tissue samples (pL1-TR)
(45,53). The locations of potential STAT binding sites and of the PCR
primers (P1 and P2) used to detect pL1-TR initiated mRNAs are also
indicated. (b) Northern blot analysis of LMP1 mRNA isolated from
two NPC tissue biopsy specimens. A 3.5-kb RNA indicative of pL1-TR
usage was detected in both samples. A 2.8-kb RNA initiating from
pED-L1 was also seen in NPC2. (c) Southern blot analysis of RT-PCR
products generated using the P1 and P2 primers and RNA isolated
from a case of EBV-positive Hodgkin’s disease. The blot was incu-
bated with an LMP1-specific 32P-labeled oligonucleotide probe. The
749-bp product is diagnostic for an LMP1 mRNA initiating from
pL1-TR. The 903-bp product was also detected in the absence of the
RT reaction and was generated from EBV genomic DNA.
TABLE 1. STAT binding sites in LMP1 and EBNA1 promoters
EBV promoter STAT site
EBNA1 (Qp) ..................................................................TT GCGAA AA
LMP1, (L1-TR)..............................................................TT CCTGG AA
LMP1 (ED-L1) ..............................................................TT TCCCG AA
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(Fig. 3b). Transfection of L1-TRp–CAT into cell lines that
were mutant for JAK1 or TYK2 resulted in decreased reporter
expression compared to that observed in the parental cell line.
In contrast, a control thymidine kinase promoter-CAT re-
porter was equally well expressed in mutant and parental cell
lines. Mutation of the STAT site within the L1-TR promoter in
L1-TRmtp–CAT led to significantly reduced CAT expression
in the parental cell line, and there was a small additional loss
of activity in the JAK1- and TYK2-negative cell lines.
The B95-8 lymphoblastoid cell line expresses LMP1 pre-
dominantly from the ED-L1 promoter, but low levels of L1-
TR-initiated transcripts can be detected in B95-8 cells by RT-
PCR analysis. B95-8 cells were subjected to RT-PCR analysis
for L1-TR-initiated mRNAs before and after treatment with
IL-6 (Fig. 4). Addition of IL-6 increased L1-TR activity, as
indicated by the increased amount of the L1-TR-specific
749-bp RT-PCR product. The amount of control EBER RNA
(EBV-encoded small nonpolyadenylated RNA) detected was
not affected by IL-6 treatment. This set of experiments pro-
vides evidence that STATs not only bind to the L1-TR pro-
moter but also positively regulate its activity.
Evidence for STAT3 as a specific regulator of the Qp and
L1-TR promoters. We have provided evidence that EBV la-
tency promoters can be activated by JAK-STAT signaling. In
normal circumstances, activation of STATs is a transient re-
sponse to cytokines or growth factors. However, certain onco-
genes, including v-Src of Rous sarcoma virus, can cause con-
stituitive STAT activation. The cellular homolog of v-Src,
c-Src, is a member of a nonreceptor protein tyrosine kinase
family that associates with the plasma membrane. In v-Src-
transformed cells, JAK1 and to a lesser extent JAK2 kinases
are constituitively activated, as are STAT3, STAT5, and
STAT1 (7, 54, 61, 62). We wished to address whether EBV
latency promoters would respond to aberrant oncogene-in-
duced STAT activation. The effect of v-Src on reporter expres-
sion directed by the EBNA1 Qp and LMP1 ED-L1 and L1-TR
promoters was examined in transfected HeLa cells (Fig. 5).
Expression from each of these three latency promoters was
significantly upregulated in the presence of v-Src. To evaluate
the extent to which the promoter response was mediated by
STAT3, v-Src was also transfected in the presence of STAT3b,
a dominant negative inhibitor of STAT3. STAT3b is a natu-
FIG. 2. The ED-L1 and L1-TR LMP1 promoters each contain STAT binding sites. (a) EMSA showing binding of purified, activated STAT1
and STAT4 to 32P-labeled oligonucleotide probes containing the potential STAT binding sites from the Qp, ED-L1, and L1-TR promoters. The
control STAT1 and STAT4 probes contain consensus STAT binding sites. Qp promotes EBNA1 expression in tumors. (b) Competition and
supershift EMSAs illustrating the specificity of STAT4 binding to the L1-TR promoter probe. The L1-TR(mt) competitor contains a mutated
STAT binding site. The Flag competitor oligonucleotide and antibody were used as controls for nonspecific effects.
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rally occurring splice variant of STAT3 that is deleted in the
carboxy-terminal activation domain (6). The v-Src-induced ac-
tivation of the EBNA1 Qp promoter was substantially inhib-
ited by STAT3b, while the activation of the LMP1 L1-TR
promoter was completely abolished. In contrast, the v-Src-
induced activation of the ED-L1 LMP1 promoter was not
affected by STAT3b, indicating that the two LMP1 promoters
are responsive to different STATs. The data strongly implicate
STAT3 as a biologically relevant STAT for the activation of the
Qp and L1-TR promoters and raise the possibility that aber-
rant activation of STAT3 may be a contributing factor in EBV-
associated pathogenesis.
NPC and Hodgkin’s disease tumor cells contain activated,
nuclear STATs. There is growing evidence for the presence of
constituitively activated STATs in a variety of tumors. For
example, constituitive activation of STAT3 has been observed
in head and neck squamous cell carcinomas (23). We have
provided evidence that the EBNA1 Qp and LMP1 promoters
expressed in tumors are STAT responsive, with the biologically
relevant STAT for Qp and the L1-TR LMP1 promoter likely to
be STAT3 while the LMP1 ED-L1 promoter apparently re-
sponds to a different STAT, possibly STAT5 or STAT1. The
issue arises as to the status of STATs in EBV-associated tu-
mors. Immunohistochemistry was used to examine the intra-
cellular localization of STAT3, STAT1, and STAT5 in archival
samples of Hodgkin’s disease and NPC tissues (Fig. 6 and 7).
The EBV status of the Hodgkin’s disease tissues was deter-
mined using standard EBER RNA in situ hybridization (data
not shown). The malignant Reed-Sternberg cells in Hodgkin’s
disease showed both cytoplasmic and nuclear staining for
STAT3. The presence of the activated, nuclear form of STAT3
was detected in both EBV-positive and EBV-negative Hodg-
kin’s disease tissue samples (Fig. 6b and d). Immunohisto-
chemistry performed for STAT1 on the same Hodgkin’s dis-
ease tissues showed a low level of activated, nuclear STAT1 in
this EBV-negative sample (Fig. 6c) but only cytoplasmic
STAT1 staining in the EBV- positive tissue (Fig. 6a). The NPC
tissue showed cytoplasmic STAT staining plus strong nuclear
staining for both STAT3 and STAT1 (Fig. 6e and f and Fig. 7a
and b) and STAT5 (Fig 7c). Interestingly, there was heteroge-
neity within the NPC tissue, with a mixture of strongly staining
positive nuclei and adjacent negative nuclei. Whether this rep-
resents true heterogeneity of STAT activation in individual
cells or has a technical basis is not currently clear.
STAT proteins are not indiscriminately activated in NPC.
Tissue was also stained for STAT4. Cytoplasmic signal was
FIG. 4. The endogenous L1-TR promoter in B95-8 cells is acti-
vated by IL-6. Southern blot analyses of RT-PCR products generated
from B95-8 lymphoblastoid cells using the P1 and P2 primers for
L1-TRp initiated mRNA (top) or primers for the polymerase III
EBER1 RNAs (bottom) are shown. cDNAs were detected using spe-
cific 32P-labeled oligonucleotide probes. Growth of B95-8 cells in me-
dium containing IL-6 increased the amount of the 749-bp L1-TR-
initiated LMP1 mRNA but did not affect EBER1 RNA levels. The
larger PCR product was also generated in the absence of the RT
reaction.
FIG. 3. The L1-TR LMP1 promoter is responsive to the STAT activators JAK1 and IL-6 and has reduced activity in JAK mutant cell lines. (a)
Reporter assay showing induction of CAT expression from L1-TRp–CAT in HeLa cells cotransfected with a JAK1 expression vector or treated
for 48 h with human IL-6 (100 ng/ml). The results shown are an average of three experiments, with the standard deviation indicated. (b) Reporter
assay comparing CAT expression from L1-TRp–CAT and L1-TR(mt)p–CAT in parental (2fTGH) versus TYK2 (U1A) and JAK1 (U4A) mutant
cells. The STAT binding site is mutated in L1-TR(mt)p–CAT. The promoter in TK-CAT is the non-STAT-regulated herpes simplex thymidine
kinase promoter. The results shown are an average of three experiments, with the standard deviation indicated.
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observed, but no evidence for nuclear, activated STAT4 was
detected (Fig. 7d). A comparison of the roles of EBNA2 and
STATs in regulating viral and cellular gene expression in EBV-
associated tumors is presented in Fig. 8.
DISCUSSION
In EBV-associated tumors, viral expression is restricted to a
limited number of the latency genes. EBNA1 is always ex-
pressed, and LMP1 is frequently expressed. We have previ-
ously shown that the Qp promoter that drives EBNA1 expres-
sion in EBV-associated tumors is JAK-STAT regulated, and
we now present evidence that this pathway also controls ex-
pression of the oncogenic LMP1 protein. The well-character-
ized ED-L1 promoter drives LMP1 synthesis in B cells, but a
second promoter located upstream of ED-L1 and inside the
terminal repeat region of the L1-TR genome also directs
LMP1 transcription in NPC (45, 53). We have now detected
L1-TR-initiated transcripts in an EBV-positive B-cell line
treated with IL-6 and in a sample of EBV-positive Hodgkin’s
disease tissue, and this suggests that usage of this promoter is
not restricted to epithelial tumors. Mobility shift assays dem-
onstrated functional STAT binding sites in the ED-L1 and
L1-TR promoters. Furthermore, reporter assays showed that
both LMP1 promoters responded to activation of the JAK-
STAT pathway, whether it be by the addition of the cytokine
IL-6 or by cotransfection of JAK1 or the oncogene v-Src.
Seven independent STAT proteins have been identified to
date. Studies utilizing modified STATs that are constituitively
activated have implicated STAT5 and STAT3 as the STATs
whose properties suggest an ability to contribute to cell trans-
formation by promoting cell cycle progression or preventing
apoptosis (4). The antiapoptotic protein Bcl-xL and the mcl-1
gene are induced by activated STAT5 and STAT3 (10, 26).
Both STAT3 and STAT5 also increase the expression of cyclin
D1, which controls cell cycle progression from G1 to S phase
(5, 37). c-Myc, a transcription factor that affects both cellular
proliferation and cell survival, is upregulated by STAT3 (33).
On the other hand, although activation of STAT1 has been
described in conjunction with either STAT5 or STAT3 in a
variety of tumors, constituitive activation of STAT1 alone ap-
pears to mediate growth-inhibitory effects.
Although STATs recognize similar binding sites in vitro,
promoter responses are STAT specific in vivo. The results of
transfection experiments using v-Src and the dominant nega-
tive STAT3b strongly suggest that STAT3 is the biologically
relevant STAT for activation of Qp and the L1-TR LMP1
promoter. Both promoters were upregulated by cotransfection
of v-Src, and this stimulation was abolished by STAT3b. Inter-
estingly, the standard LMP1 promoter response to v-Src was
not affected by STAT3b, suggesting that one of the other
STATs activated by v-Src, either STAT5 or STAT1, is respon-
sible for the STAT-mediated responses of this promoter. The
presence of two LMP1 promoters that respond to different
STATs may expand the circumstances in which LMP1 can be
expressed. For example, the malignant Reed-Sternberg and
Hodgkin cells in EBV-positive Hodgkin’s disease tumors ex-
press particularly high levels of LMP1 and, in our immunohis-
tochemical analyses, contained nuclear, activated STAT3 but
FIG. 5. The EBNA1 Qp and both LMP1 promoters are activated
by v-Src-induced signaling and differentially repressed by interference
with STAT3 function. Reporter assay in HeLa cells cotransfected with
the EBV latency Qp-CAT, ED-L1–CAT, and L1-TR–CAT construc-
tions and either control vector DNA (vector), an expression plasmid for
v-Src, or v-Src plus a dominant negative STAT3 inhibitor (STAT3b). The
results shown are an average of three experiments, with the standard de-
viation indicated.
FIG. 6. NPC and Hodgkin’s disease Reed-Sternberg cells contain
activated nuclear STATs. Immunohistochemical analyses of STAT
localization in NPC and Hodgkin’s disease tissue samples are shown.
(b and d) STAT3 staining in EBV-positive (b) and EBV-negative (d)
Hodgkin’s disease tissue. The malignant Reed-Sternberg cells are in-
dicated by arrowheads. (a and c) STAT1 staining in EBV-positive (a)
and EBV-negative (c) Hodgkin’s disease tissue. (e and f) NPC tissue
stained for STAT1 (e) and STAT3 (f). STATs were detected using
anti-STAT1 and anti-STAT3 primary antibodies (Santa Cruz), and
reactive complexes were visualized using StrpABComplex/horseradish
peroxidase (Dako). Tissue was counterstained with hematoxylin.
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not STAT1. We detected LMP1 expression from the L1-TR
promoter in Hodgkin’s disease tissue, and this would be con-
sistent with STAT3 regulation of this promoter. On the other
hand, we and others (45) found evidence for both ED-L1-
and L1-TR-initiated LMP1 transcripts in NPC tissues, and, in
contrast to the results obtained with Hodgkin’s disease, we also
detected nuclear STAT5 and STAT1 in NPC tissue.
Promoter responsiveness to STATs is also modified by in-
teractions with other transcription factors. In this regard, it is
interesting that SP1 and SP3 contribute to the basal activity of
the L1-TR promoter (45, 53). Transcriptional cooperativity
between Sp1 and STAT3 has been described for IL-6-mediated
activation of the C/EBPd promoter (8), and Sp1 and STAT1
also directly interact to produce cooperative transcriptional
responses (36, 63).
The observation that the EBNA1 and LMP1 genes that are
expressed in EBV-associated tumors are STAT regulated,
along with the recognition that STATs are frequently aber-
rantly activated in human cancers, including those that are
EBV associated, provides a background for speculating on the
etiology of EBV-associated tumorigenesis. Long-term EBV
latency is established in memory B cells. Only LMP2A and the
BamHI-A rightward transcripts are constitutively expressed in
these cells (13, 39). Long-lived memory B cells originate in
germinal centers, where cells are selected in part on the basis
of competition for antigen. In transgenic mice expressing
Bcl-2, the antiapoptotic function of Bcl-2 allows survival in the
memory compartment of B cells that lack affinity-enhancing
somatic gene mutations (48). LMP1 plays an antiapoptotic role
that includes upregulation of cellular Bcl-2 expression and is
mediated through NF-kB induction (28). We have argued that
LMP1 expression is STAT regulated. Primary B lymphocytes
do not express activated STATs (31, 58), but antigen receptor
engagement in B cells induces nuclear expression of STAT5
and STAT6 and interactions between B cells and follicular
FIG. 7. Further evaluation of the intracellular localization of
STATs in NPC tissues. Immunohistochemical staining was performed
as described in the legend to Fig. 6. STAT3 and STAT5 staining is
visible within tumor cell nuclei. In contrast, STAT4 staining is re-
stricted to the cytoplasm. (a) STAT3 (magnification, 3400). (b) STAT3
(magnification, 3600). (c) STAT5 (magnification, 3600). (d) STAT4
(magnification, 3600).
FIG. 8. Model for in vivo EBV gene regulation and tumorigenesis. In primary infection, EBNA2 regulates the expression of the nuclear EBNAs
and the LMP genes including LMP1 and modulates cellular gene expression. The strong immune response to the immunogeneic EBNAs limits
the occurrence of EBNA2-expressing tumors to immunocompromised individuals. During in vivo latency, in the absence of EBNA2, the EBNA1
and LMP1 genes are regulated by STATs. Chronic activation of STATs through a natural cytokine signaling event such as inflammation or through
aberrant oncogene-activated signaling may upregulate EBV EBNA1 and LMP1 expression and predispose the cell to EBV-driven tumorigenesis.
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dendritic cells and T cells in the germinal center elicit cyto-
kine responses that also involve STATs (16, 31, 52). Transient
stimulation of LMP1 expression in the germinal center could
provide an additional survival signal that would allow EBV-
carrying memory cells to transit the germinal center without
undergoing apoptosis. Further, the expression of EBNA1
would ensure maintainance of the EBV genome in B cells
undergoing transient proliferation in the germinal center.
The sporadic nature of EBV-associated tumorigenesis in the
face of ubiquitous, lifelong infection has always posed a co-
nundrum that can only partially be explained in terms of host
immune regulation. The natural STAT responsiveness of the
Qp EBNA1 and LMP1 promoters may be one of the factors in
this sporadic pathogenesis. It has proven difficult to detect
EBV infection in normal mucosal epithelium despite the fact
that virus is continuously shed into the saliva of EBV-seropos-
itive individuals. Activated STATs are not usually present in
normal epithelium, but nuclear STAT3 has been detected in
the normal mucosa of patients with head and neck cancers
(23). Entry of EBV into a cell that has already undergone
disregulation of STAT signaling could be a predisposing event
for EBV-associated tumorigenesis. Along similar lines, we
observed nuclear STAT3 in both EBV-negative and EBV-
positive samples of Hodgkin’s disease tissue, suggesting that
aberrant STAT3 activity may be a common feature of the
development of this malignancy and may precede EBV infec-
tion. However, there does also exist the possibility for estab-
lishment of a positive autoregulatory loop of LMP1 expression
and STAT activation (Fig. 9). LMP1 signaling induces the
expression of IL-6 and the epidermal growth factor receptor
(EGFR) (18, 20, 25, 38) both of which activate STATs, includ-
ing STAT3. Upregulation of EGFR expression is seen in squa-
mous cell carcinoma of the head and neck, and it has been
proposed that EGFR overexpression is an early event in the
development of these tumors (49). LMP1 is also able to acti-
vate JAK3, whose targets include STAT5 (22). Further, LMP1
induces the expression of JNK, one of the kinases that facili-
tate STAT activity through serine phosphorylation of the
STAT transcriptional activation domain. Thus, prolonged ac-
tivation of normal JAK-STAT signaling through, for example,
chronic inflammation may, in some circumstances, be sufficient
to establish a pattern of EBV gene expression that is poten-
tially both self-sustaining and tumorigenic.
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